Acute GVH disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Twenty-three patients developed grade 1 to 4 aGVHD at a median of 37 days (range, 15 to 79 days) after HCST.
|
25881755 |
2015 |
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Participants were 60 children (median age of 5; inter quartile range: 3.07-5.76), including 31 females and 29 males, 91.7% of them were affected by acute lymphoblastic leukemia (ALL), and 8.3% by acute myeloid leukemia (AML).Five children had undergone HCST.
|
29065156 |
2017 |
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Participants were 60 children (median age of 5; inter quartile range: 3.07-5.76), including 31 females and 29 males, 91.7% of them were affected by acute lymphoblastic leukemia (ALL), and 8.3% by acute myeloid leukemia (AML).Five children had undergone HCST.
|
29065156 |
2017 |
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, adoptive transfer of chPD1 T cells could be a novel therapy for lymphoma and inclusion of the Dap10 co-stimulatory domain in chimeric antigen receptors may induce a preferential cytokine profile and T-cell differentiation phenotype for anti-tumour therapies.
|
28670716 |
2017 |
Aortic Aneurysm, Abdominal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two different members of the NK pathway, HCST and GRZB, which act at different steps in the NK-pathway, were actively transcribed and translated into proteins in the same cells in the AAA tissue demonstrated by double staining.
|
25993291 |
2015 |
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Results shown suggest that inhibitors of DAP10 and DAP12 or other proteins involved in this signaling pathway will be attractive therapeutic targets for the treatment of LGLL and other autoimmune diseases and syndromes.
|
19075187 |
2009 |
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Participants were 60 children (median age of 5; inter quartile range: 3.07-5.76), including 31 females and 29 males, 91.7% of them were affected by acute lymphoblastic leukemia (ALL), and 8.3% by acute myeloid leukemia (AML).Five children had undergone HCST.
|
29065156 |
2017 |
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, adoptive transfer of chPD1 T cells could be a novel therapy for lymphoma and inclusion of the Dap10 co-stimulatory domain in chimeric antigen receptors may induce a preferential cytokine profile and T-cell differentiation phenotype for anti-tumour therapies.
|
28670716 |
2017 |
Cooley's anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This encouraging result has revised our previous conception about haploidentical HCST for thalassaemia major and strongly suggests that HD HSCT is a feasible and safe method for thalassaemia major patients.
|
29962035 |
2018 |
Hemorrhagic cystitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
BK virus hemorrhagic cystitis is a complication of HCST.
|
29388318 |
2018 |
Invasive Fungal Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Our primary objective was to describe the incidence of proven or probable invasive fungal infections (IFIs), a devastating complication of hematopoietic stem cell transplant (HSCT), in HCST in a middle-income country.
|
29679436 |
2018 |
Leukemia, Large Granular Lymphocytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.
|
19075187 |
2009 |
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Participants were 60 children (median age of 5; inter quartile range: 3.07-5.76), including 31 females and 29 males, 91.7% of them were affected by acute lymphoblastic leukemia (ALL), and 8.3% by acute myeloid leukemia (AML).Five children had undergone HCST.
|
29065156 |
2017 |
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, adoptive transfer of chPD1 T cells could be a novel therapy for lymphoma and inclusion of the Dap10 co-stimulatory domain in chimeric antigen receptors may induce a preferential cytokine profile and T-cell differentiation phenotype for anti-tumour therapies.
|
28670716 |
2017 |
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
We verified MSLN expression in primary human GC tissues and GC cell lines and then redirected T cells with a CAR containing the MSLN scFv (single-chain variable fragment), CD3ζ, CD28, and DAP10 intracellular signaling domain (M28z10) to target MSLN.
|
30777106 |
2019 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The NKG2D-DAP10 receptor complex activates natural killer (NK) cells and costimulates effector T cell subsets upon engagement of ligands that can be conditionally expressed under physiologically harmful conditions such as microbial infections and malignancies.
|
16329186 |
2006 |
Malignant transformation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
NKG2D naturally associates with native costimulatory molecule DAP10, effectively generating a second-generation CAR against multiple ligands upregulated during malignant transformation including MIC-A, MIC-B and the UL-16 binding proteins.
|
30180944 |
2018 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Consistent with these signaling activities, above-threshold expression of NKG2D-DAP10 in a ligand-bearing tumor line increases its bioenergetic metabolism and proliferation, thus suggesting functional similarity between this immunoreceptor and tumor growth factor receptors.
|
21321202 |
2011 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The chPD1-Dap10 T cells also had enhanced in vivo persistence and anti-tumour efficacy compared with chPD1-CD28 T cells.
|
28670716 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, NKG2D-DAP10 receptor complexes may activate NK and T cell responses against MICA-bearing tumors.
|
10426994 |
1999 |
Respiratory Distress Syndrome, Adult
|
0.010 |
Biomarker
|
disease |
BEFREE |
RNA-Seq was performed on 11 patients with ARDS (5 that had undergone HSCT and 6 that had not) and 12 patients with sepsis without ARDS (5 that that had undergone HCST and 7 that had not).
|
30665420 |
2019 |
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
RNA-Seq was performed on 11 patients with ARDS (5 that had undergone HSCT and 6 that had not) and 12 patients with sepsis without ARDS (5 that that had undergone HCST and 7 that had not).
|
30665420 |
2019 |
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
RNA-Seq was performed on 11 patients with ARDS (5 that had undergone HSCT and 6 that had not) and 12 patients with sepsis without ARDS (5 that that had undergone HCST and 7 that had not).
|
30665420 |
2019 |
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We verified MSLN expression in primary human GC tissues and GC cell lines and then redirected T cells with a CAR containing the MSLN scFv (single-chain variable fragment), CD3ζ, CD28, and DAP10 intracellular signaling domain (M28z10) to target MSLN.
|
30777106 |
2019 |
Tuberculosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, our results suggest that during Mtb infection DAP10 is required for maximal cytolytic activity of CD8 T cells.
|
21122940 |
2011 |